Project Grant R01CA269651
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$453K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $616,495 Project Grant under CFDA 93.396 - Cancer Biology Research to The University of Texas MD Anderson Cancer Center. The grant supports research to define the biological role of sulfatide in the development and progression of pancreatic cancer precursor lesions, test whether inhibition of sulfatide metabolism is a viable cancer interception strategy, and conduct a proof-of-concept study using mass spectrometry imaging to identify positive margins...
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...
This Project Grant award of $513,542 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to define the role of the p53 protein in regulating chaperone-mediated autophagy (CMA) and the impact on tumor development. The research aims to elucidate the mechanisms by which p53 activates CMA, a selective form of autophagy, and how this regulation of CMA and cellular metabolism contributes to p53's tumor suppressive functions. The award was granted to The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $192,240 to The University of Texas MD Anderson Cancer Center to conduct research on the functional contribution of extracellular vesicles in pancreatic cancer. The research aims to investigate how cancer cell-derived extracellular vesicles modulate the tumor microenvironment to facilitate pancreatic cancer initiation, progression, and metastasis. The goal is to identify novel...
This $139,445 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will fund research by the Regents of the University of Michigan to characterize the role of mesothelial-derived cancer-associated fibroblasts (CAFs) in the pathogenesis of pancreatic ductal adenocarcinoma (PDA). The central hypothesis is that mesothelial cells give rise to a distinct, immunomodulatory population of CAFs that influence the PDA tumor microenvironment. Through in...
The National Cancer Institute (NCI) awarded a $2,679,816 Project Grant (CFDA 93.396 Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai. The 5-year grant, effective August 1, 2025, will support an integrated research program focused on understanding the role of mutant p53 proteins in tumor progression, invasion, and metastasis. The program consists of four interrelated projects that will use systematic studies, molecular mechanisms, and transcriptional regulation approaches...
This Project Grant award for $536,186.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct research on APOBEC3A and its role in tumor evolution and intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC). The award will fund this research project over a 3-year period from Sep 30, 2023 to Sep 29, 2026. As...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,306,991.00 to The University of Texas M.D. Anderson Cancer Center to support research on "ORGANOID-BASED MODELING AND THERAPEUTIC TARGETING OF TP53-MUTATED ACUTE MYELOID LEUKEMIA". The award commenced on August 1, 2025 and is scheduled for completion on July 31, 2029. The research aims to advance the understanding and treatment of acute...
This Project Grant award of $662,938, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Northwestern University to investigate the role of gain-of-function mutant p53 proteins in acute myeloid leukemia (AML). The central objective is to determine how these p53 mutations promote leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure, which may contribute to therapy resistance in AML....
This $1,130,538 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC) using a newly developed anti-Tn (AREMAB6) monoclonal antibody. The key objectives are to: 1) determine how the Tn antigen enhances PDAC progression and identify Tn-expressing glycoproteins; 2) validate the role of natural killer cells in AREMAB6-mediated...